Hepatitis B Vaccine and Dialysis: Current Issues

Kane M. . Global programme for control of hepatitis B infection. Vaccine 1995 (suppl); 13: S47–9.

Snydman D.R. , Bregman D. , Bryan J. . Hemodialysis-associated hepatitis in the United States, 1974. J Infect Dis 1977; 135: 687–91.

Martin P. , Friedman L.S. . Chronic viral hepatitis and the management of chronic renal failure. Kidney Int 1995; 47: 1231–41.

Tokars Jl , Miller E.R. , Alter M.J. , Arduino M.J. . National surveillance of dialysis-associated diseases in the United States, 1977. Semin Dial 2000; 13: 75–85.

Urbanowicz W. , Wawrzynowicz-Syczewska M. , Boròn-Kaczmarska A. . HBV and HCV infections in relation to the chosen genetic features in hemodialyzed patients (letter). Nephron 2000; 85: 357.

Lewis-Ximenez L.L. , Oliveira J.M. , Mercadante L.A.C. , De Castro L. , Santa Catharina W. , Stuver S. , Yoshida C.F.T. . Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection. Nephron 2000; 87: 19–26.

Jankovic N. , Cala S. , Nadinic B. , Varlai-Knobloch V. , Pavlovic D. . Hepatitis C and hepatitis B virus infection in hemodialysis patients and staff: a two year follow-up. Int J Artif Organs 1994; 17: 137–40.

Covic A. , lancu L. , Apetrei C. . Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999; 14: 40–5.

Vladutiu D. , Cosa A. , Neamtu A. . Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a black map ? J Viral Hepat 2000; 7: 313–9.

Cendoroglo Neto M. , Draibe S.A. , Silva A.E.B. . Incidence and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10: 240–6.

The hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee. Morb Mortal Wkly Rep 1991; 40: 1–19.

Lemon S.M. , Thomas D.L. . Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196–204.

Lau J.Y. , Wright T.L. . Molecular virology and pathogenesis of hepatitis B. Lancet 1993; 342: 1335–40.

Ohnuma H. , Machida A. , Okamoto H. . Allelic subtypic determinants of hepatitis B surface antigen (i and t) that are distinct from d/y or w/r. J Virol 1993; 67: 927–32.

Murphy B.L. , Maynard J.E. , Le Bouvier G.L. . Viral subtypes and cross-protection in hepatitis B virus infections in chimpanzees. Intervirology 1974; 3: 378–81.

Szmuness W. , Stevens C.E. , Harley E.J. . Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype protection. N Engl J Med 1982; 307: 1481–6.

Waters J.A. , Kennedy M. , Voet P. . Loss of the common ‘A’ determinant of hepatitis B surface antigen by a vaccine-induced escape mutants. J Clin Invest 1992; 90: 2543–7.

Itoh Y. , Takyi E. , Ohnuma H. . A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 1986; 83: 9174–7.

Neurath A.R. , Kent S.B.H. , Parker K. . Antibodies to a synthetic peptide from the pre-S 120-145 region of the hepatitis B virus envelope are virus-neutralizing. Vaccine 1986; 4: 35–40.

Milich D.R. , Thornton G.B. , Neurath A.R. , Kent S.B. , Michel M.L. , Tiollais P. , Chisari F.V. . Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 228: 1195–9.

Oulich D.R. , McLachlan A. , Chisari F.V. . Immune response to the pre-S (1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass non-responsiveness of the pre-S(2) and S regions of HBsAg. J Immunol 1986; 137: 315–9.

Zanetti A.R. , Tanzi E. , Romanò L. , Grappasonni I. . Vaccination against hepatitis B: the Italian strategy. Vaccine 1993; 11: 521–4.

Recombivax H.B. . West Point, PA.: Merck, 1995 (package insert).

Engerix-B. Philadelphia: Smith Kline Beecham Pharmaceuticals, 1995 (package insert).

Beasley R.P. , Lin C.C. , Hwang L.Y. , Chien C.S. . Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 1981; 2: 1129–33.

Chang M.H. , Chen C.J. , Lai M.S. for the Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855–9.

Centers for Disease Control and Prevention. Hepatitis B virus infection: a comprehensive immunization strategy to eliminate transmission in the United States, 1999 update. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (in press).

Center for Disease Control and Prevention: Notice to readers: recommended childhood immunization schedule-United States, 2000. MMWR 2000; 49: 35–8.

American Academy of Pediatrics. Active and passive immunization. In: Peter G. , ed. 1997 Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL. American Academy of Pediatrics, 1997: 1.

Centers for Disease Control and Prevention. Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR 1985; 34: 105–13.

Rangel M.C. , Coronado V.G. , Euler G.L. , Strikas R.A. . Vaccine recommendations for patients on chronic dialysis. Semin Dial 2000; 13: 101–7.

Rodby R.A. , Trenholme G.M. . Vaccination of the dialysis patient. Semin Dial 1991; 4: 102–5.

Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W, and the Dialysis Vaccine Trial Study Group. Hepatitis B vaccine in patients receiving hemodialysis. N Engl J Med 1984; 311: 496–501.

Crosnier J. , Jungers P. , Courouce A.M.A. . Randomised placebo controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients. Lancet 1981; 1: 797–800.

Desmyter J. , de Groote G. , Colaert J. and the Leuven Renal Transplantation Collaborative Group. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983; 2: 1323–8.

Miller E.R. , Alter M.J. , Tokars Jl . Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33: 356–60.

Bommer J. , Ritz E. , Andrassy K. . Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc EDTA 1983; 30: 161–8.

Kohler H. , Arnold W. , Renschin G. , Dormeyer H.H. , Meyer Zum Buschenfelde K.H. . Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124–8.

Benhamou E. , Couroucè A.M. , Jungers P. , Laplanche A. , Degos F. , Brangier J. , Crosnier J. . Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143–7.

Carreno V. , Mora I. , Escuin F. . Vaccination against hepatitis B in renal dialysis units: short or normal vaccination schedule ? Clin Nephrol 1985; 24: 215–20.

De Graeff P.A. , Dankert J. , De Zeuw D. , Gips C.H. , van der Hem G.K. . Immune response to two different hepatitis B vaccines in haemodiaiysis patients: a two year follow-up. Nephron 1985; 40: 155–60.

Van Geelen J.A. , Schalm S.W. , de Vissen E.M. , Heijtink R.A. . Immune response to hepatitis B vaccine in hemodialysis patients. Nephron 1987; 45: 216–8.

Steketee R.W. , Ziamik M.E. , Davis J.P. . Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. Am J Epidemiol 1988; 127: 772–82.

Pasko M.T. , Bartholomew W.R. , Beam R.T. , Amsterdam D. , Cunningham E.E. . Long-term evaluation of the hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1998; 11: 326–31.

Drachman R. , Isachson M. , Rudenski B. , Drukker A. . Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol Dial Transplant 1989; 4: 372–4.

Walz G. , Kunzendorf U. , Haller H. . Factors influencing the response to hepatitis B vaccination of hemodialysis patients. Nephron 1989; 51: 474–7.

Zucmann-Caillat S. , Gimenez J.J. , Albouze G. . HLA heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int 1993; 43(suppl): S157–60.

Jilg W. , Schmidt M. , Weinel B. . Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. J Hepatol 1986; 3: 190–5.

Bruguera M , Cremades M. , Mayor A. , Sanchez Tapias J.M. , Rodes J. . Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Postgrad Med J 1987; 63: 155–8.

Guan R. , Choong L. . Immunogenicity of a recombinant DNA hepatitis B vaccine in patients with chronic renal failure. Epidemiol News Bull 1989; 15: 45–6.

Docci D. , Cipolloni P.A. , Mengozzi S. , Baldrati L. , Capponcini C. , Feletti C. . Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients. A two year follow-up. Nephron 1992; 61: 352–4.

Docci D. , Baldrati L. , Capponcini C. , Feletti C. . Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients (letter). Am J Nephrol 1992; 12: 477.

Fleming S.J. , Moran D.M. , Cooksley W.G.E. , Faoagali J.L. . Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect 1991; 22: 251–7.

Sennesael J.J. , van der Niepen P. , Verbeelen D.L. . Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121–8.

Buti N. , Viladomiu L. , Jardi R. , Olmos A. . Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 1992; 12: 144–7.

Dentico P. , Buongiorno R. , Volpe A. . Long-term immunogenicity and protective efficacy of recombinant DNA yeast-derived vaccine in hemodialysis patients. J Nephrol 1993; 6: 95–7.

Navarro J.F. , Teruel J.L. , Mateos M.L. , Mareen R. , Ortuno J. . Antibody level after hepatitis B vaccination in hemodialysis patients: Influence of hepatitis C virus infection. Am J Nephrol 1996; 16: 95–7.

Marangi A.L. , Giordano R. , Montanaro A. . Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination. Am J Kidney Dis 1994; 23: 537–42.

Fabrizi F. , Di Filippo S. , Marcelli D. , Guarnori I. , Raffaele L. , Crepaldi M. , Erba G.F. , Locatelli F. . Recombinant hepatitis B vaccine use in chronic hemodialysis patients: Long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72: 536–43.

Fernandez E. , Betru M.A. , Gomez R. , Montoliu J. . Response to the hepatitis B virus vaccine in haemodalysis patients: influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol Dial Transplant 1996; 11: 1559–63.

Lombardi M. , Pizzarelli F. , Righi M. . Hepatitis B vaccination in dialysis patients and nutritional status. Nephron 1992; 61: 266–8.

Mitwalli A. . Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417–20.

Peces R. , de la Torre M. , Alcazar R. , Urra J.M. . Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am J Kidney Dis 1997; 29: 239–45.

Stachowski J. , Pollok M. , Barth C. , Maciejewski J. , Baldamus C.A. . Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating costimulatory processes in antigen presentation and recognition. Nephrol Dial Transplant 1994; 9: 144–52.

Girndt M. , Kohler H. , Schiedelm-Weick E. , Schlaek J. , Meyer Zum Buschenfelde K.H. , Fleicher B. . Production of interleukin-6, tumor necrosis factor and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559–65.

Vagelli G. , Calabrese G. , Mazzotta A. , Pratesi G. , Gonella M. . More about response to hepatitis B vaccine in hemodialysis patients (letter). Nephron 1988; 49: 171.

Alper C.A. , Kriskall M.S. , Marcus-Bagley D. . Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989; 32: 708–12.

Pol S. , Legendre C. , Mattlinger B. , Berthelot P. , Krein H. . Genetic basis of nonresponse to hepatitis B vaccine in hemodialysis patients. J Hepatology 1990; 11: 385–7.

Dukes C.S. , Street A.C. , Starling J.F. , Hamilton J.D. . Hepatitis B vaccination and booster in predialysis patients: A 4-year analysis. Vaccine 1993; 11: 1229–32.

CDC. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40 RR-13: 1–25.

Task Force on Adult's Immunization. Guide for Adult Immunization, 2nd ed. American College of Physicians, Philadelphia, 1990.

Hadler S.C. , Francis D.P. , Maynard J.E. . J. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209–14.

Hess G. , Kreiter F. , Kosters W. , Deusch K. . The effect of granulocyte-macrophage colony stimulating factor (M-CSF) on hepatitis B vaccination in haemodialysis patients. J Viral Hepat 1996; 3: 149–53.

Kapoor D. , Aggarwal S.R. , Singh N.P. , Thakur V. , Sarin S.K. . Granulocyte-macrophage colony stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat 1999; 6: 405–9.

Anandh U. , Bastani B. , Ballal S. . Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients (letter). Am J Nephrol 2000; 20: 53–6.

Evans T.G. , Schiff M. , Graves B. . The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin Nephrol 2000; 54: 138–42.

Quiroga J.A. , Castillo I. , Porres J.C. . Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990; 12: 661–3.

Haubitz M. , Ehlerding G. , Beigel A. , Heuer U. , Hemmerlinh A.E. , Thoma H.A. . Clinical experience with a new recombinant hepatitis B vaccine in previous non-responders with chronic insufficiency. Clin Nephrol 1996; 45: 180–2.

Ayli M.D. , Ensary C. , Ayli M. , Mandiroglu F. , Mut S. . Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients (letter). Nephron 2000; 84: 291–2.

Rawer P. , Willems W.R. , Breidenbach T. , Guttmann W. , Pabst W. , Schutterle G. Seroconversion rate, hepatitis B vaccination, and zinc supplementation. Kidney Int 1987; 32 (suppl 22): S149–52.

Brodersen H.P. , Holtkamp W. , Larbig D. . Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: A multicentre study (letter). Nephrol Dial Transplant 1995; 10: 1780.

Donati D. , Gastaldi L. . Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1988; 50: 133–6.

Jungers P. , Devillier P. , Salomon H. , Cerisier J.E. , Couroucè A.M. . Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 344: 856–7.

Mauri M.J. , Valles M. and The Collaborative Group of Girona. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Nephrol Dial Transplant 1997; 12: 729–32.

Ozener C. , Fak A.S. , Avsar E. , Cinar S. , Lawrence R. , Akoglu E. . The effect of alpha interferon therapy and short-interval administration on response to hepatitis B vaccine in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1339–40.

Ono K. , Kashiwagi S. . Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients. Nephron 1991; 1: 47–51.

Vlassopoulos D. , Arvanitis D. , Ulis D. , Katopodis K. , Louizou K. , Hadjiconstantinou V. . Low repeated doses of intradermal hepatitis B vaccine produce protective levels of antibodies in hemodialysis patients, non-responding to usual and double multiple doses. J Nephrol 1994; 7: 340–1.

Vlassopoulos D.A. , Arvanitis D.K. , Lilis D.S. , Loizou Kl , Hadjiconstantinou V.E. . Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. Int J Artif Organs 1999; 22: 739–43.

Mettang T. , Schenk U. , Thomas S. . Low dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. Nephron 1996; 72: 192–6.

Propst T. , Propst A. , Lhotta K. , Vogel W. , Konig P. . Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041–5.

Charest A.F. , McDougall J. , Goldstein M.B. . A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976–82.

Waite N.M. , Thomson L.G. , Goldstein M.B. . Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995; 5: 1930–4.

Chang P.C. , Scharnder-van der Meer A.M. , van Dorp W.T. , van Leer E. . Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 1996; 11: 191–3.

Fabrizi F. , Andrulli S. , Bacchini G. , Corti M. , Locatelli F. . Intradermal versus intramuscular hepatitis B vaccination in non-responsive chronic dialysis patients: A prospective study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204–11.

Michel P. , Janin G. , El Yafi S. , Chevallier P. , Girard P. , Laville M. , Trepo C. . Improvement of immune response in dialysis patients to Hevac B vaccine after multiple injections of vaccine. Proc EDTA-ERA 1985; 22: 1077–82.

Zuckerman A. . Appraisal of intradermal immunisation against hepatitis B. Lancet 1987; 1: 435–6.

Bommer J. , Grussendorf M. , Jilg W. . Vaccination against hepatitis B in patients with renal insufficiency. Proc EDTA-ERA 1984; 21: 300–5.

Jungers P. , Chaveau P. , Couroucè A.M. , Mattlinger B. , Crosnier J. . Hepatitis B vaccine in non-dialysed uraemic patients: preliminary results. Proc EDTA-ERA 1985; 22: 1073–6.